SDF-1 binding nucleic acids
The present invention is related to an L nucleic acid that binds to an SDF-1.
1. An L-nucleic acid molecule, or a homolog thereof, wherein the L-nucleic acid molecule comprises SEQ ID NO:117 and said homolog comprises homology to SEQ ID NO:117 of at least 85%, and wherein said L-nucleic acid molecule and said homolog bind SDF-1.
2. The L-nucleic acid molecule according to claim 1 , wherein said SDF-1 comprises a human SDF-1.
3. The L-nucleic acid molecule according to claim 1 , wherein the L-nucleic acid molecule is an antagonist of an SDF-1.
4. The L-nucleic acid according to claim 1 , further comprising a modification.
5. The L-nucleic acid according to claim 4 , wherein said modification comprises a hydroxyl ethyl starch (HES) moiety or a polyethylene glycol (PEG) moiety.
6. The L-nucleic acid according to claim 4 , wherein said modification consists of a straight or a branched PEG moiety.
7. The L-nucleic acid according to claim 6 , wherein said straight or said branched PEG moiety comprises a molecular weight from 2 to 180 kD.
8. The L-nucleic acid according to claim 5 , wherein said HES moiety comprises a molecular weight from 10 to 130 kD.
9. A pharmaceutical composition comprising the L-nucleic acid according to claim 1 and a pharmaceutically acceptable excipient, a pharmaceutically active agent or combination thereof.
10. The L-nucleic acid molecule according to claim 4 , wherein said modification is at the 5′ end of the L-nucleic acid molecule or the homolog.
11. The L-nucleic acid molecule according to claim 4 , wherein said modification is at the 3′ end of the L-nucleic acid molecule or the homolog.
12. The L-nucleic acid molecule according to claim 6 , wherein said straight or said branched PEG moiety comprises a molecular weight from 40 kD to 120 kD.
13. The L-nucleic acid molecule according to claim 1 , further comprising a linker.
14. The L-nucleic acid molecule according to claim 4 , wherein said modification comprises a biotin.